Immunotherapy in NMSCs

CE / CME

Immunotherapy Advances in the Management of Nonmelanoma Skin Cancers

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 09, 2023

Expiration: May 08, 2024

Zeynep Eroglu
Zeynep Eroglu, MD
Bethany Withycombe
Bethany Withycombe, PharmD, BCOP

Activity

Progress
1
Course Completed

Immunotherapy Advances in the Management of Nonmelanoma Skin Cancers

In this module, Zeynep Eroglu, MD, a medical oncologist in the Department of Cutaneous Oncology at the Moffitt Cancer Center in Tampa, Florida, presents key advances in immunotherapies for the management of nonmelanoma skin cancers (NMSCs), including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC). Bethany Withycombe, PharmD, BCOP, a clinical pharmacy specialist, also from Moffitt Cancer Center, provides guidance on the monitoring and management of key immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options (CCO) plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with NMSCs do you provide care for in a typical month?

Which of the following best describes your specialty?

A 73-year-old man was diagnosed with BCC on the right side of his nose and underwent Mohs surgery to remove the lesion. After 8 years, he presents with a lesion in the same area, and the workup reveals a 2.5-cm lesion with poorly defined borders. He is given vismodegib 150 mg/day for 33 months but discontinues treatment because of muscle spasms, loss of taste, and anorexia.

Which of the following would be the most appropriate next step for managing this patient’s BCC?

A patient with BCC is receiving an anti–PD-1 therapy and develops grade 3 diarrhea.

In your clinical practice, how would you manage this patient’s grade 3 diarrhea?

For a patient with locally advanced cSCC (lacSCC) who is not a candidate for curative surgery or curative radiation, which of the following would be the preferred treatment option based on current evidence and recommendations?